Large-cap health care company Johnson & Johnson has moved -0.3% this afternoon, reaching $152.29 per share. In contrast, the average analyst target price for the stock is $179.1.
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company is based in the United States. Johnson & Johnson currently returns an annual dividend yield of 3.0%.
Make Sure to Consider the Following Before Buying Johnson & Johnson:
Johnson & Johnson has moved -7.0% over the last year.
JNJ has a forward P/E ratio of 14.0 based on its EPS guidance of 10.84.
Over the last 6 years, earnings per share (EPS) have been growing at a compounded average rate of 55.8%.
The company has a price to earnings growth (PEG) ratio of 2.91.
Its Price to Book (P/B) ratio is 5.27
Johnson & Johnson Has Irregular Cash Flows
|Date Reported||Cash Flow from Operations ($ k)||Capital expenditures ($ k)||Free Cash Flow ($ k)||YoY Growth (%)|
Johnson & Johnson's free cash flows have a decent average of $24.4 Billion over the last 6 years, but they are highly variable since their coefficient of variability is 104706446633.7%. The compounded average growth rate over this period is 0.0%.